SLC19A1 rs2283729: Folate Carrier Genetics Explained

What each genotype means

What Is rs2283729 and Where Is It Located?

The variant rs2283729 is a single-nucleotide polymorphism (SNP) situated within the SLC19A1 gene on human chromosome 21. Like many non-coding or intronic variants found across the human genome, it represents a single DNA base change between an ancestral allele and an alternative allele. Rather than completely deactivating a protein, common polymorphisms in this genomic region are typically evaluated for subtle regulatory effects, such as altering gene transcription, transcript stability, or alternative splicing. In nutrigenomic profiling, rs2283729 is frequently cataloged alongside better-known variants in the same locus to capture inherited variations in micronutrient transport. Because it sits in linkage disequilibrium with other genetic landmarks in SLC19A1, researchers often examine whether rs2283729 tracks with broader functional haplotypes that govern how effectively cells express folate uptake machinery.

The Biological Role of the SLC19A1 Gene

The SLC19A1 gene provides instructions for producing the reduced folate carrier 1 (RFC1) transmembrane protein, a solute carrier that facilitates the bidirectional movement of 5-methyltetrahydrofolate and other reduced folates across cell membranes into mammalian tissues. RFC1 operates primarily as an organic anion antiporter and is expressed throughout the body, including the intestinal epithelium, placenta, and liver. In addition to natural nutritional folates, RFC1 serves as the primary gateway for synthetic antifolate medications like methotrexate. Folates are indispensable cofactors for one-carbon metabolism, supporting de novo nucleotide biosynthesis, DNA repair, and S-adenosylmethionine-mediated methylation pathways. Because cells cannot synthesize folate endogenously, the structural integrity and operational kinetics of carriers such as RFC1 are critical for maintaining healthy intracellular folate pools.

Current Research and Strength of Evidence

Scientific literature investigating rs2283729 focuses largely on whether variations in the SLC19A1 locus subtly alter folate transport efficiency or influence baseline blood folate concentrations. While major coding changes in the gene can produce severe, rare folate transport deficiencies, common SNPs like rs2283729 demonstrate modest statistical associations rather than direct clinical consequences. Existing nutrigenomic studies have explored links between SLC19A1 variations and biomarker shifts in red blood cell folate, plasma homocysteine, and differential pharmacokinetics of folate-mimicking drugs. Nevertheless, the evidence strength for rs2283729 in isolation is currently classified as limited. Findings across cohorts are mixed, with many reported effects failing to reach strict genome-wide significance or demonstrating strong dependence on background dietary intake and maternal-fetal interactions.

How Common Is the Variant Across Populations?

The rs2283729 variant is a widespread polymorphism found globally across diverse human ancestries. Population genetics surveys and reference repositories, such as the 1000 Genomes Project and gnomAD, indicate that the minor allele maintains a frequency between approximately 0.40 and 0.45 across major continental populations. Because both the major and minor alleles are heavily represented, all three possible genotypes—homozygous reference, heterozygous, and homozygous alternative—are common in the general public. This balanced distribution suggests that carrying one or two copies of the minor allele is a normal element of human genetic diversity rather than a rare pathogenic mutation. Consequently, the presence of the minor allele does not indicate a rare inborn error of metabolism.

What You Can and Cannot Conclude From Your Results

Discovering your rs2283729 genotype provides an educational glimpse into your personal nutrigenomic profile, but it is not a standalone diagnostic indicator of folate deficiency or disease risk. Genetic variants in folate pathways exert subtle influences that operate alongside total dietary folate consumption, alcohol intake, renal clearance, and other genes such as MTHFR. A specific genotype does not mean you are deficient in vitamin B9, nor does it mandate high-dose supplementation. Furthermore, because SLC19A1 also handles antifolate pharmaceuticals such as methotrexate, readers must not use this genotype to alter any medical therapy. Any concerns regarding folate status, nutritional planning, or medication dosing should always be addressed directly with a physician or qualified healthcare provider.

Frequently asked questions

Sources & further reading